The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan.
about
Quantitative Imaging Biomarkers of NAFLDUltrasound imaging of the liver and bile ducts - expectations of a clinicianNoninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound TechniqueHepatic steatosis and fibrosis: Non-invasive assessment.Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?Combined acoustic radiation force impulse, aminotransferase to platelet ratio index and Forns index assessment for hepatic fibrosis grading in hepatitis B.Shear wave elastography results correlate with liver fibrosis histology and liver function reserve.Cost-utility analysis of nonalcoholic steatohepatitis screening.Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysisEstimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.Transient elastography: Kill two birds with one stone?Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART).Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography with diabetes mellitus in patients with chronic liver disease.Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis BReview article: the management of paediatric nonalcoholic fatty liver disease.Factors associated with significant liver fibrosis assessed using transient elastography in general population.Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease.Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease.Predicting Hepatic Steatosis in Living Liver Donors via Noninvasive Methods.A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives.Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan(®)).The intersection of nonalcoholic fatty liver disease and obesity.Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults.Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis.Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease.Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.The Association of Gut Microbiota with Nonalcoholic Steatohepatitis in Thais.Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification.Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis.Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease.
P2860
Q26768664-B6AB8E79-234F-4F8B-8E44-F0424A1BA7EEQ26775551-AD71A078-BA89-4E86-8E6B-1547A82E7D17Q27318751-1AF25062-F62D-4547-AB08-945684A70822Q28077200-B9D55003-5885-4A1E-AAF6-C6065B50A63FQ28079445-E2CA68EC-4D9E-49BA-B890-171C2D408221Q30383654-6E80DE16-F397-4667-8E3C-542C30A276AFQ30384025-CA68055D-A4CA-460D-8766-53797CFD7268Q30385602-6B1068C6-7148-4D08-8266-4D4D01C79216Q30393929-34D3FE72-E871-4EBD-A713-B79FD9DFF2EEQ30412738-26062D25-C9EA-4BD6-97C6-B0527F8A5A37Q30441653-47DA9443-7223-462A-B48B-0E91C31306B9Q30454363-952B3D28-70E8-4F7F-9AF0-90A13E5303C7Q33718346-5FB7557A-5C80-417A-BA74-E5FCE5108ABBQ33778556-478B0D31-5788-4CC9-95DD-DC8DEC27C516Q34029988-BAF76E6C-960D-4E24-8C54-997672DBE94AQ34036808-BF3A32C7-8D35-4E8C-83E3-156043D15BB9Q34440962-D70B2367-C64E-4595-B291-4835C09D7108Q35012048-6C0A218D-6AAF-4E58-BBDB-4E5CC2C6394FQ36658454-E96A9F59-50C9-4342-82AB-4AC626EFB901Q36952218-A229EE1C-300F-4C64-85AD-CE0E617BD232Q37206110-A7F81F3E-718F-482B-80FB-552750B580E2Q37632267-CF6B7C06-D5E5-4F0A-B1F6-F911E8580789Q37724690-86BA4797-5979-42AD-B77A-14928EB02B1DQ38070696-31A3256C-21BF-42DF-A213-50E7A6E7A844Q38494198-237617D5-B5F4-4835-9EF3-AEE0CFAB5BAFQ38635589-F04DCE58-1D42-4E28-AB07-766A6E16D6ADQ38714560-8ECA2398-B48C-4B0C-867A-61D096C80402Q38974249-07935FE5-21ED-4A4F-A3A7-E85FCCB58A51Q39877513-0A677F3F-FE9C-4235-9FD4-CDD6DE851398Q40116616-61948F1E-833C-43F9-8FA0-31152BDB37E1Q40360505-4872A707-60EB-40A6-A729-358C40D0E409Q40367115-8FAEA379-72D6-43DD-97EE-9C9F1BE84D2BQ41094423-8BCF34D7-E77A-49AC-A892-70B6DA7F38E1Q41185516-F2CD7974-4D94-4900-9850-729DC817AFFDQ45325830-027DDB91-ECF4-45AF-8446-3F3074E6F678Q45942296-EA67EE90-CD61-4005-ADAE-44996D54B596Q52571014-C5731DCD-EA52-462E-BB29-8650DBB1A215Q53217662-ADC51304-021B-42B7-80C2-EC4B765C240AQ54226681-EA06CC3E-5B49-4C44-8996-43F9BEC515F9Q55045481-A63C31AF-EB0E-4692-986B-7C227ECDBE61
P2860
The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The controlled attenuation par ...... of steatosis using Fibroscan.
@en
The controlled attenuation parameter
@nl
type
label
The controlled attenuation par ...... of steatosis using Fibroscan.
@en
The controlled attenuation parameter
@nl
prefLabel
The controlled attenuation par ...... of steatosis using Fibroscan.
@en
The controlled attenuation parameter
@nl
P2093
P1476
The controlled attenuation par ...... of steatosis using Fibroscan.
@en
P2093
P356
10.1016/J.CLINRE.2011.08.001
P577
2011-09-15T00:00:00Z